GNI Ltd. Identifies Important Regulator and Druggable Target Implicated in Human Cancers and Neurodegenerative Disorders

22 May 2007

·www.biospace.com

TOKYO--(BUSINESS WIRE)--GNI Ltd., a leading biopharmaceutical company in Asia, and its Chinese affiliate Shanghai Genomics, Inc., announced today that their researchers had identified an important cell growth regulator and druggable target likely associated with human cancers and neurodegenerative disorders. The findings of the research are to be published by the Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world's most-cited multidisciplinary scientific serials, during the week of May 21, 2007.

Organizations

GNI Group Ltd.Shanghai Genomics, Inc.Emerson Process Management Regulator Technologies, Inc.

Indications

NeoplasmsNeurodegenerative Diseases

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.